![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lynparza Receives European Approval for Pancreatic Cancer
Lynparza Receives European Approval for Pancreatic Cancer
July 9, 2020
The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) for treatment of adults with germline BRCA-mutated metastatic pancreatic cancer who have not progressed after 16 weeks of chemotherapy.
The approval was based on the results of a phase 3 clinical trial in which Lynparza increased the time patients lived without disease progression or death to 7.4 months compared to 3.8 months on placebo.
The FDA approved Lynparza for the same indication in December 2019.
Upcoming Events
-
21Oct